Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(9):1373–1376. doi: 10.1038/bjc.1997.232

Elevated serum levels of S100 and survival in metastatic malignant melanoma.

J Buer 1, M Probst 1, A Franzke 1, S Duensing 1, J Haindl 1, M Volkenandt 1, F Wittke 1, R Hoffmann 1, A Ganser 1, J Atzpodien 1
PMCID: PMC2228235  PMID: 9155061

Abstract

Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.

Full text

PDF
1374

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Lopez Hänninen E., Kirchner H., Franzke A., Körfer A., Volkenandt M., Duensing S., Schomburg A., Chaitchik S., Poliwoda H. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer. 1995 Jun;31A(6):876–881. doi: 10.1016/0959-8049(94)00459-5. [DOI] [PubMed] [Google Scholar]
  2. Fagnart O. C., Sindic C. J., Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem. 1988 Jul;34(7):1387–1391. [PubMed] [Google Scholar]
  3. Gaynor R., Herschman H. R., Irie R., Jones P., Morton D., Cochran A. S100 protein: a marker for human malignant melanomas? Lancet. 1981 Apr 18;1(8225):869–871. doi: 10.1016/s0140-6736(81)92142-5. [DOI] [PubMed] [Google Scholar]
  4. Glass A. G., Hoover R. N. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989 Oct 20;262(15):2097–2100. [PubMed] [Google Scholar]
  5. Guo H. B., Stoffel-Wagner B., Bierwirth T., Mezger J., Klingmüller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995 Oct;31A(11):1898–1902. doi: 10.1016/0959-8049(95)00087-y. [DOI] [PubMed] [Google Scholar]
  6. Heimdal K., Hannisdal E., Gundersen S. Regression analyses of prognostic factors in metastatic malignant melanoma. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1219–1223. doi: 10.1016/0277-5379(89)90418-5. [DOI] [PubMed] [Google Scholar]
  7. Isobe T., Ishioka N., Okuyama T. Structural relation of two S-100 proteins in bovine brain; subunit composition of S-100a protein. Eur J Biochem. 1981 Apr;115(3):469–474. doi: 10.1111/j.1432-1033.1981.tb06225.x. [DOI] [PubMed] [Google Scholar]
  8. Karlsson M., Jungnelius U., Aamdal S., Boeryd B., Carstensen J., Kågedal B., Westberg R., Wingren S. Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma. Int J Cancer. 1996 Jan 3;65(1):1–5. doi: 10.1002/(SICI)1097-0215(19960103)65:1<1::AID-IJC1>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  9. Koh H. K. Cutaneous melanoma. N Engl J Med. 1991 Jul 18;325(3):171–182. doi: 10.1056/NEJM199107183250306. [DOI] [PubMed] [Google Scholar]
  10. Kunter U., Buer J., Probst M., Duensing S., Dallmann I., Grosse J., Kirchner H., Schluepen E. M., Volkenandt M., Ganser A. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst. 1996 May 1;88(9):590–594. doi: 10.1093/jnci/88.9.590. [DOI] [PubMed] [Google Scholar]
  11. Legha S. S. Current therapy for malignant melanoma. Semin Oncol. 1989 Feb;16(1 Suppl 1):34–44. [PubMed] [Google Scholar]
  12. Sirott M. N., Bajorin D. F., Wong G. Y., Tao Y., Chapman P. B., Templeton M. A., Houghton A. N. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993 Nov 15;72(10):3091–3098. doi: 10.1002/1097-0142(19931115)72:10<3091::aid-cncr2820721034>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  13. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991 Nov 16;338(8777):1227–1229. doi: 10.1016/0140-6736(91)92100-g. [DOI] [PubMed] [Google Scholar]
  14. Trent J. M., Meyskens F. L., Salmon S. E., Ryschon K., Leong S. P., Davis J. R., McGee D. L. Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med. 1990 May 24;322(21):1508–1511. doi: 10.1056/NEJM199005243222107. [DOI] [PubMed] [Google Scholar]
  15. Xerri L., Grob J. J., Battyani Z., Gouvernet J., Hassoun J., Bonerandi J. J. NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br J Cancer. 1994 Dec;70(6):1224–1228. doi: 10.1038/bjc.1994.477. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES